CYP2C19 and gastric cancer: The risk of gastric cancer (aHR 2.47) in the CYP2C19 non‐extensive metabolizers, that is, the intermediate and poor metabolizers, was elevated compared with that in extensive metabolizers; however, this difference was not statistically significant (Tables S3 and S4).